Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
News|Articles|February 3, 2025
Broadley-James Expands Distribution of Distek’s Benchtop Controllers in UK and Ireland
Author(s)Feliza Mirasol
Under the expanded distribution service, Distek’s BIOne Benchtop Controllers will now be made available across the UK and Ireland.
Advertisement
US-based Distek, a manufacturer of laboratory testing instruments, announced on Jan. 28, 2025 that Broadley-James, a UK-headquartered supplier of pH and dissolved oxygen sensors for life science applications, is now distributing Distek's BIOne Benchtop Controllers across the United Kingdom and Ireland. This expansion builds on a partnership the two companies began in 2017 in which they introduced the BIOne Single-Use Bioreactor (2 L) for mammalian cell culture (1).
Distek’s portfolio has since expanded, and continues to expand, now featuring a comprehensive range of benchtop bioreactor solutions including:
- BIOne 250 Bioprocess Control for microbial applications
- BIOne 1250 Bioprocess Control for mammalian and microbial applications
- BIOne Single-Use Bioreactors for cell culture and cell-free applications
- BIOne Single-Use Fermenters for a variety of microbial applications
The offering of a complete portfolio such as this enables researchers and scientists in the UK and Ireland to access Distek’s bioprocessing solutions, which provide flexibility and are user-friendly. These bioprocessing solutions are applicable to both mammalian and microbial operations (1).
Reference
1. Distek. Broadley-James Expands Portfolio with Distek BIOne Benchtop Controllers in the UK & Ireland. Press Release. Jan. 28, 2025.
Advertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5